Search
Hip Hop 2 SToP video It didn’t take long for shyness to make way for excitement when a group of children from Dampier Peninsula communities got
Perth researchers discovered a naturally occurring virus living in the city’s waterways that could potentially fight antibiotic-resistant superbugs.
Wiping out childhood ear infections could become a reality thanks to new research identifying the main bacteria responsible for recurrent ear infections and repeat ear surgeries.
The ORIGINS Project is a decade-long longitudinal study of more than 18,000 individuals including mothers, partners and children, as part of a collaboration between The Kids Research Institute Australia and Joondalup Health Campus.
A number of organisations have created COVID-19 resources specifically developed for Aboriginal and Torres Strait Islander people.
View the full catalogue of The Kids Research Institute Australia COVID-19 video resources.
Research
Cystic FibrosisCystic fibrosis (CF) is the most common chronic, life-shortening genetic condition affecting young Australians. There is no cure but researchers are working to prevent the onset of lung disease.
Research
Berrembi Jarragboo-Boorroo Wajawoorroo Men'Gawoom Gijam (Gija Healthy Skin Story): Two-Way Learning for Healthy SkinRemote-living Aboriginal children in Australia contend with higher rates of skin infections than non-Indigenous children. This work was embedded within a stepped-wedge, cluster randomised controlled trial aiming to halve the rate of skin infections in remote Kimberley communities. It outlines and reflects upon the co-development of a health promotion resource in partnership with the East Kimberley community of Warmun, whilst understanding community perceptions of its impact.
Research
Australian Group on Antimicrobial Resistance surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns in Australian children and adolescents 2022 - 2023Between January 2022 and December 2023, there were 1,827 bloodstream infection (BSI) isolates in 1,745 children and adolescents reported to the Australian Group on Antimicrobial Resistance (AGAR) surveillance outcome programs, with 40% of episodes in children aged < 12 months.
Research
Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS studyAim: To describe the real-world effects of trofinetide in individuals with Rett syndrome (RTT) using the 18-month follow-up analysis of the LOTUS study.